×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MNKD – mannkind corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MNKD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/6
03:46 am
mnkd
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion [Seeking Alpha]
Medium
Report
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion [Seeking Alpha]
1/29
01:59 pm
mnkd
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration [Globe and Mail, The (Toronto, Canada)]
Low
Report
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration [Globe and Mail, The (Toronto, Canada)]
1/26
10:43 am
mnkd
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
1/26
10:31 am
mnkd
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets [Globe and Mail, The (Toronto, Canada)]
Low
Report
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets [Globe and Mail, The (Toronto, Canada)]
1/26
06:21 am
mnkd
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy [Yahoo! Finance]
Medium
Report
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy [Yahoo! Finance]
1/26
06:05 am
mnkd
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
Low
Report
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
1/23
12:56 pm
mnkd
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Medium
Report
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
1/22
04:00 am
mnkd
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative [Yahoo! Finance]
Medium
Report
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
08:30 pm
mnkd
Form 4 MANNKIND CORP For: Jan 08 Filed by: Tross Stuart A
Low
Report
Form 4 MANNKIND CORP For: Jan 08 Filed by: Tross Stuart A
1/8
04:07 pm
mnkd
Form 144 MANNKIND CORP Filed by: Tross Stuart A
Low
Report
Form 144 MANNKIND CORP Filed by: Tross Stuart A
12/29
08:00 pm
mnkd
Form 4 MANNKIND CORP For: Dec 24 Filed by: Castagna Michael
Low
Report
Form 4 MANNKIND CORP For: Dec 24 Filed by: Castagna Michael
12/19
08:00 pm
mnkd
Form 4 MANNKIND CORP For: Dec 17 Filed by: Castagna Michael
Low
Report
Form 4 MANNKIND CORP For: Dec 17 Filed by: Castagna Michael
12/16
08:15 pm
mnkd
Form 4 MANNKIND CORP For: Dec 12 Filed by: Castagna Michael
Low
Report
Form 4 MANNKIND CORP For: Dec 12 Filed by: Castagna Michael
12/15
04:03 pm
mnkd
Form 8-K/A MANNKIND CORP For: Oct 07
Low
Report
Form 8-K/A MANNKIND CORP For: Oct 07
12/12
04:26 pm
mnkd
Form 144 MANNKIND CORP Filed by: Castagna Michael
Neutral
Report
Form 144 MANNKIND CORP Filed by: Castagna Michael
12/4
07:32 pm
mnkd
Form 4 MANNKIND CORP For: Dec 02 Filed by: Castagna Michael
Low
Report
Form 4 MANNKIND CORP For: Dec 02 Filed by: Castagna Michael
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/10
Form DEFA14A MANNKIND CORP
11.5%
1/20 3 Top-Notch “Strong Buy” Stocks Under $3 [Yahoo! Finance News] 11.4%
9/11 MannKind: Investor Conference And Scripts - The Story Is Evolving [Seeking Alpha] 10.8%
1/10 MannKind Co. (NASDAQ: MNKD) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 7.3%
5/29 5 Years Since MannKind Received FDA Approval For Afrezza Doubts Swirl [Seeking Alpha] 5.3%
1/7 MannKind Co. (NASDAQ: MNKD) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. 4.5%
7/31 Form 4 MANNKIND CORP For: Jul 31 Filed by: Barton Courtney 4.5%
2/20 MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) 4.1%
9/9 MannKind Corporation (MNKD) presents at H.C. Wainwright 21st Annual Global Investment Conference (Transcript) [Seeking Alpha] 4.1%
5/14 MannKind Co. (NASDAQ: MNKD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock. 3.9%
1/20 3 Top-Notch “Strong Buy” Stocks Under $3 [Yahoo! Finance News] 11.4%
9/11 MannKind: Investor Conference And Scripts - The Story Is Evolving [Seeking Alpha] 10.8%
1/10 MannKind Co. (NASDAQ: MNKD) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 7.3%
5/29 5 Years Since MannKind Received FDA Approval For Afrezza Doubts Swirl [Seeking Alpha] 5.3%
1/7 MannKind Co. (NASDAQ: MNKD) had its "outperform" rating re-affirmed by analysts at Svb Leerink Llc. 4.5%
7/31 Form 4 MANNKIND CORP For: Jul 31 Filed by: Barton Courtney 4.5%
2/20 MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) 4.1%
9/9 MannKind Corporation (MNKD) presents at H.C. Wainwright 21st Annual Global Investment Conference (Transcript) [Seeking Alpha] 4.1%
5/14 MannKind Co. (NASDAQ: MNKD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock. 3.9%
TOP News Decliners
3/17
MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic
-15.3%
2/25 Form 10-K MANNKIND CORP For: Dec 31 -14.6%
11/6 Q3/2019 9/30/2019 EPS -0.050 ZacksConsensus -0.070 ActVsEst 0.020 - Beat -11.4%
8/7 MannKind Corporation 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -10.8%
5/7 Form 10-Q MANNKIND CORP For: Mar 31 -9.9%
1/27 MannKind Co. (NASDAQ: MNKD) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -9.5%
1/22 Should You Worry About MannKind Corporation's (NASDAQ:MNKD) CEO Pay? [Yahoo! Finance News] -8.9%
5/16 Form 4 MANNKIND CORP For: May 14 Filed by: Tross Stuart A -7.3%
4/30 MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock. -7.1%
1/28 MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.6%
2/25 Form 10-K MANNKIND CORP For: Dec 31 -14.6%
11/6 Q3/2019 9/30/2019 EPS -0.050 ZacksConsensus -0.070 ActVsEst 0.020 - Beat -11.4%
8/7 MannKind Corporation 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -10.8%
5/7 Form 10-Q MANNKIND CORP For: Mar 31 -9.9%
1/27 MannKind Co. (NASDAQ: MNKD) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -9.5%
1/22 Should You Worry About MannKind Corporation's (NASDAQ:MNKD) CEO Pay? [Yahoo! Finance News] -8.9%
5/16 Form 4 MANNKIND CORP For: May 14 Filed by: Tross Stuart A -7.3%
4/30 MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock. -7.1%
1/28 MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: